Prof. Nicola Curtin
Professor of Experimental Therapeutics
- Email: n.j.curtin@ncl.ac.uk
- Telephone: +44 (0) 191 246 4415
- Fax: +44 (0) 191 246 4415
- Address: Northern Institute for Cancer Research
School of Clinical & Laboratory Sciences
Medical School
University of Newcastle upon Tyne
NE2 4HH
Professor of Experimental Cancer Therapeutics since 2006. Team leader for DNA damage signalling and repair projects within CR-UK Drug Development Programme
Selected Publications
- Curtin NJ. PARP inhibitors for cancer therapy. Expert Reviews in Molecular Medicine 2005, 7(4), 1-20.
- Curtin NJ; Newell DR; Harris AL. Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole. Biochemical Pharmacology 1989, 38(19), 3281-8.
- Curtin NJ; Harris AL. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochemical Pharmacology 1988, 37(11), 2113-20.
- Bassendine MF; Curtin NJ; Loose H; Harris AL; James OF. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. Journal of Hepatology 1987, 4(3), 349-56.
- Curtin NJ; Snell K. Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo. British Journal of Cancer 1983, 48(4), 495-505.
- Curtin NJ; Snell K. Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo. Biochemical Society Transactions 1980, 8(1), 94.
